Compare OIS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | RCKT |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.3M | 428.6M |
| IPO Year | 2001 | N/A |
| Metric | OIS | RCKT |
|---|---|---|
| Price | $9.08 | $3.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $8.00 | ★ $30.27 |
| AVG Volume (30 Days) | 891.9K | ★ 2.2M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $655,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $2.19 |
| 52 Week High | $9.19 | $11.27 |
| Indicator | OIS | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 39.28 |
| Support Level | $8.41 | $3.00 |
| Resistance Level | $9.07 | $3.63 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 88.48 | 20.33 |
Oil States International Inc is a provider of manufactured products and services to the energy, industrial and military sectors. Manufactured products include engineered capital equipment as well as products consumed in the drilling, well construction and production of oil and natural gas. The company sells its products and services to national oil and natural gas companies, oil and natural gas companies, onshore and offshore drilling companies and other oilfield services, defense and industrial companies. The company operates through three business segments, Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. It gains maximum revenue from Offshore Manufactured Products.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.